Actelion News Today

Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by th...

Dublin, May 31, 2021 (GLOBE NEWSWIRE) -- The "Antidiarrhoeals Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. The global antidiarrhoeals market is expected to grow from $0.14 billion in 2020 to $0.19 billion in 2021 at a compound annual growth rate (CAGR) of 35.7%. Major players in the antidiarrheal drugs market are GlaxoSmithKline, Actelion, Perrigo, Lupin and Glenmark Pharmaceuticals.The growth is mainl...

02 marzo 2021 17:14 Fonte: Adnkronos #salute-e-benessere AUSTIN, Texas, March 2, 2021 /PRNewswire/ -- Beyond Batten Disease Foundation (BBDF) is pleased to announce an agreement with Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, to provide Zavesca® (miglustat) for the development of BBDF-101, a proprietary combination of miglustat and trehalose to treat juvenile Batten disease (CLN3). Janssen will provide drug supply for the clinical trials and Extended...